vaborbactam

Description: Vaborbactam (formerly known as RPX7009; trade name: Vabomere) is novel potent and broad spectrum non-beta-lactam beta-lactamase inhibitor discovered by Rempex Pharmaceuticals. It is not effective as an antibiotic by itself, but it restores the potency of existing antibiotics by inhibiting the beta-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections. In the United States, the combination drug meropenem/vaborbactam (Vabomere) was approved by the FDA (Food and Drug Administration) on 8/29/2017 for treating complicated urinary tract infections and pyelonephritis.

References: Antimicrob Agents Chemother. 2016 Aug 22; 60(9):5454-8.